跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,663 条关于
“C5 complement pathway”
全部
7,663
临床试验
1,971
药物
144
机构
16
资讯
5,532
7个月前
RNA Interference Therapy Market Expands with 90+ Drugs in Development Across 40+ Companies
去年
Kira Pharmaceuticals' KP104 Shows Sustained Efficacy and Safety in PNH Phase 2 Trial
3年前
FDA Approves Avacincaptad Pegol for Geographic Atrophy
去年
ImmunAbs Receives FDA Clearance for Phase 2 Trial of IM-101 Complement Inhibitor in Myasthenia Gravis
3年前
Iptacopan Shows Promise in Complement-Inhibitor-Naïve PNH Patients
2年前
FDA Approves Fabhalta (Iptacopan) as First Oral Monotherapy for PNH
去年
Breakthrough Treatments Transform Landscape for Rare Hemolytic Anemias: From C5 Inhibitors to Novel Therapeutic Approaches
去年
Omeros Advances Zaltenibart Phase 3 Trials for PNH with Potential Superiority Over Current Treatments
去年
Novartis' FABHALTA Poised to Transform Treatment Landscape for Multiple Complement-Mediated Diseases
去年
Zilbrysq Market Projected to Grow 21.64% Annually Through 2030 Following FDA Approval for Myasthenia Gravis
第 1 页,共 554 页
上一页
下一页